INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER
申请人:Pauls Heinz W.
公开号:US20100105900A1
公开(公告)日:2010-04-29
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
The present invention is directed to a compound of Formula (I):
or a form thereof, wherein X
1
, X
2
, X
3
, X
4
, R
1
, R
2
and R
3
are as defined herein, useful as tryptase inhibitors.
Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
申请人:Pauls Heinz W.
公开号:US08680282B2
公开(公告)日:2014-03-25
A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Inhibitors of carnitine palmitoyltransferase and treating cancer
申请人:Pauls Heinz W.
公开号:US08410150B2
公开(公告)日:2013-04-02
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
The present invention is directed to a compound of Formula (I):
or a form thereof, wherein X
1
, X
2
, X
3
, X
4
, R
1
, R
2
and R
3
are as defined herein, useful as tryptase inhibitors.